

# **Rolling Revision of the WHO Guidelines for Drinking-Water Quality**

**Draft for review and comments  
(Not for citation)**

## **Dichloroacetic acid in drinking-water**

Background document for development of  
*WHO Guidelines for Drinking-water Quality*



**World Health Organization  
August 2004**

© World Health Organization 2004

Requests for permission to reproduce or translate WHO publications - whether for sale or for non-commercial distribution - should be addressed to Publications (Fax: +41 22 791 4806; e-mail: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damage incurred as a result of its use.

***First Draft prepared by***  
***Diana Wong and Joyce Morrissey Donohue***

Health and Ecological Criteria Division  
Office of Science and Technology, Office of Water  
United States Environmental Protection Agency  
Washington, D.C.

---

## TABLE OF CONTENTS

1.	GENERAL DESCRIPTION .....	1
1.1	Identity .....	1
1.2	Physicochemical properties .....	1
1.3	Organoleptic properties.....	2
1.4	Major uses.....	2
2.	ANALYTICAL METHODS .....	2
3.	ENVIRONMENTAL LEVELS AND HUMAN EXPOSURE.....	2
3.1	Air .....	2
3.2	Water.....	3
3.3	Food .....	3
3.4	Estimated total exposure and relative contribution of drinking-water .....	4
4.	KINETICS AND METABOLISM IN LABORATORY ANIMALS AND HUMANS.....	4
5.	EFFECTS ON HUMANS.....	5
6.	EFFECTS ON LABORATORY ANIMALS AND <i>IN VITRO</i> TEST SYSTEMS .....	6
6.1	Acute exposure .....	7
6.2	Short-term exposure.....	7
6.3	Long-term exposure .....	9
6.4	Reproductive toxicity, embryotoxicity and teratogenicity .....	10
6.5	Mutagenicity and related end-points.....	11
6.6	Carcinogenicity .....	12
7.	GUIDANCE VALUES.....	15
8.	ACHIEVABILITY OF HEALTH-BASED GUIDELINES .....	16
9.	REFERENCES .....	17

## 1. GENERAL DESCRIPTION

Paragraph 1

This profile is based on EPA's IRIS Toxicological Review for DCA (US EPA, 2003). It is also based on the WHO Guidelines for Drinking-water Quality (WHO, 1996), and the WHO Environmental Health Criteria 216. Disinfectants and Disinfectant By-Products document (WHO, 2000).

### 1.1\_ Identity

Paragraph 1

<i>Compound</i>	<i>CAS no.</i>	<i>Molecular formula</i>
Dichloroacetic acid, Dichloroethanoic acid	79-43-6	Cl <sub>2</sub> CHCOOH

### 1.2 Physicochemical properties (Weast, 1988; Vershueren, 1977; Budavari et al., 1989; HSDB, 2001)

Paragraph 1

<i>Property</i>	<i>Dichloroacetic acid<sup>1</sup></i>
Boiling point (°C)	194
Melting point (°C)	13.5
Density (g/cm <sup>3</sup> )	1.56 at 20 °C
Vapour pressure (mm Hg)	0.179 at 25 °C
Dissociation constant (pKa) at 25 °C	1.26
Water solubility (g/litre)	86.3
Log octanol–water partition coefficient	0.92

<sup>1</sup>Conversion factor in air: 1 ppm = 5.27 mg/m<sup>3</sup>

### **1.3 Organoleptic properties**

Paragraph 1

No information is available on the taste or odour threshold of dichloroacetic acid in water.

### **1.4 Major uses**

Paragraph 1

Dichloroacetic acid is used as a chemical intermediate in the synthesis of organic materials, as an ingredient in pharmaceuticals and medicines, as a topical astringent, and as a fungicide (Hawley, 1981; HSDB, 2001).

## **2. ANALYTICAL METHODS**

Paragraph 1

The chloroacetic acids can be detected in water by EPA Method 552.1, EPA Method 552.2, or Standard Method 6251B (APHA, 1998). In EPA Method 552.1, the haloacetic acids are extracted on a miniature anion exchange column and converted to methyl esters in the eluant prior to analysis. EPA Method 552.2 involves a liquid–liquid extraction procedure, after which the acetic acids are converted to methyl esters (US EPA, 1995). Both EPA Methods use gas chromatography and electron capture detection. Standard Method 6251B uses a micro liquid–liquid extraction procedure combined with gas chromatography and electron capture detection. Method detection limits range from <0.1 to 0.4 µg/litre. The practical quantification level (PQL) for dichloroacetic acid is approximately 1 µg/litre (personal communication from Pat Fair, US EPA, Cincinnati, Ohio).

## **3. ENVIRONMENTAL LEVELS AND HUMAN EXPOSURE**

### **3.1 Air**

Paragraph 1

No information is available on the concentrations of dichloroacetic acid in air. It is not a volatile compound and is not expected to be present in air unless dissolved in atmospheric water vapour.

Paragraph 2

Reimann et al. (1996) reported that 0.05 to 4 µg/litre of dichloroacetic acid were measured in rain water: Rainwater in Germany contained 1.35 µg of dichloroacetic acid per litre (IARC, 1995).

## 3.2 Water

### Paragraph 1

Chlorinated acetic acids are formed from organic material during water chlorination (Coleman et al., 1980; WHO, 2000). Concentrations of dichloroacetic acid measured in various water sources were summarized by IARC (1995) as follows: in Japan, chlorinated drinking-water contained 4.5 and 7.5 µg of dichloroacetic acid; in Australia, a maximum concentration of 200 µg/litre was found for dichloroacetic acid in chlorinated water.

### Paragraph 2

Data for drinking-water supplies in the USA indicate that dichloroacetic acid was detected in groundwater and surface water distribution systems at mean concentrations of 6.9 and 17 µg/litre, respectively. Concentrations ranged from <1.0–99 µg/litre in surface water distribution systems and <1.0–71 µg/litre in ground water systems (US EPA, 2001).

### Paragraph 3

Dichloroacetic acid has also been detected in swimming pool water. In a German study of 15 indoor and 3 outdoor swimming pools (Clemens & Scholer, 1992), dichloroacetic acid concentrations averaged 5.6 µg/litre and 119.9 µg/litre in indoor and outdoor pools, respectively. The mean concentration of dichloroacetic acid in three indoor pools in the United States was 419 µg/litre (Kim & Weisel, 1998). The difference between this study and the lower levels reported in the German study may have been due to differences in the amounts of chlorine used to disinfect swimming pools, sample collection time relative to chlorination of the water, or addition or exchanges of water in the pools.

## 3.3 Food

### Paragraph 1

Chlorine is used in food production and processing, including the following: disinfection of chicken in poultry plants; processing of seafoods, poultry and red meats; oxidizing and bleaching in the flour industry. It is also used in sanitizing equipment and containers; and cooling heat-sterilized foods (US EPA, 1994). Therefore, dichloroacetic acid is likely be found as disinfection byproducts in meat and other food products.

### Paragraph 2

Reimann et al. (1996) examined the concentrations of dichloroacetic acid in a limited number of samples of several vegetables, fruits, grain, and beer. Dichloroacetic acid concentrations ranged from <0.9 to 3.5 µg/kg in vegetables, <0.6 to 11.1 µg/kg in grains, 0.8 to 19.8 µg/kg in flours/breads and 1.5 to 15.2 µg/litre in beer. It was not detected in fruits or tomatoes. Raymer et al. (2001) found that dichloroacetic acid was stable in water during boiling and was taken up by

---

foods during cooking in water. Carrots, green beans, pinto beans and chicken were tested; uptake ranged from 11% for chicken to 85% for pinto beans.

### **3.4 Estimated total exposure and relative contribution of drinking-water**

Paragraph 1

The available data are sufficient to demonstrate that food and water are relevant exposure sources for exposure to dichloroacetic acids. The data are not adequate to quantify the contributions of each source for an overall assessment of exposure.

## **4. KINETICS AND METABOLISM IN LABORATORY ANIMALS AND HUMANS**

Paragraph 1

Dichloroacetic acid is rapidly absorbed into the blood stream from the gastrointestinal tract in rats and mice (Stacpoole, 1987; James et al., 1998; Schultz et al., 1999, Schultz et al., 2002) and via both the oral and dermal routes in humans (Stacpoole et al., 1998a; Kim & Weisel, 1998). It is initially distributed to liver and muscle, and subsequently to other target organs (Evans, 1982; James et al., 1998).

Paragraph 2

In young adults rats administered a single radiolabelled gavage dose of 50 mg/kg of body weight of sodium dichloroacetate (42.4 mg radiolabelled dichloroacetate/kg of body weight), the radioactivity present as percent of the administered dose was localized in the muscle (11.9%), liver (6.19%), gastrointestinal tract (3.74%), fat (3.87%), and kidney (0.53%). "Other tissues," including plasma, spleen, heart, skin, bone, brain, lung, and testes, accounted for 9.46% of the administered dose (James et al., 1998). In rats, dogs, and humans given single doses of sodium dichloroacetate intravenously, average half-lives of the parent compound in plasma were 2.97, 20.8, and 0.43 h, respectively. The apparent dose dependence in plasma clearance suggested that metabolic transformation becomes the rate-limiting step at high doses (Lukas et al., 1980).

Paragraph 3

DCA is dechlorinated to glyoxylate and then oxidized to oxalate all of which are excreted in the urine. Transamination of glyoxylate forms glycine and can distribute the label from dichloroacetic acid to urinary glycine conjugates such as hippuric acid, (Stacpoole, 1989; James et al., 1998; Stacpoole et al., 1998a). Some dichloroacetic acid is also converted to carbon dioxide and eliminated via expired air (James et al., 1998). Rats administered repeated high doses of dichloroacetic acid also eliminate unmetabolized compound, (Gonzales-Leon et al., 1997; Cornett et al., 1999).

Paragraph 4

Following a single oral dose of 50 mg/kg in humans, urinary excretion of unchanged dichloroacetate was negligible after 8 h, and cumulative excretion was less than 1% of the total dose in all subjects (Lukas et al., 1980). However two human subjects who ingested drinking-water containing 4 or 6.3 µg/L dichloroacetic acid excreted 2 to 5% of the dose as unmodified DCA in the urine shortly after exposure (Kim et al., 1999). The plasma elimination of DCA by rats was slowed by administration of a single prior dose of DCA, suggesting that dichloroacetic acid inhibits its own metabolism (James et al., 1997). The mean plasma half-life increased from 63.3 minutes to 374 minutes in human volunteers after intravenous administration of five 50 mg/kg doses (Curry et al., 1985).

Paragraph 5

The enzyme that catalyzes the glutathione-dependent oxygenation of dichloroacetate has been identified as glutathione-S-transferase (GST)-zeta (Tong et al., 1998a, 1998b). GST-zeta is identical to maleylacetoacetate isomerase, an enzyme in the metabolic pathway for tyrosine catabolism (Fernandez-Cannon and Penalva, 1998). There are species and intraspecies differences in the activity of GST-zeta with dichloroacetic acid as a substrate (Tong et al., 1998a). Blackburn et al. (2001) identified 5 variant forms of the enzyme among a group of 128 Caucasian blood donors (GST-zeta 1a-1a, 1b-1b, 1c-1c, 1d-1d, and 1e-1e). The most frequent human variant (1c-1c) identified by Blackburn et al. (2001) was found to be the least active in the metabolism of dichloroacetic acid (Tzeng et al., 2000) while the most active variant (1a-1a) had a low distribution in the population. Blackburn et al. (2001) did not find the 1e-1e variant among the population studied.

Paragraph 6

Dichloroacetic acid inhibition of GST-zeta appears to be the result of the formation of a covalent complex between GSH and dichloroacetic acid that can either dissociate releasing glyoxylate as a product, or covalently bind to a nucleophilic residue in the enzyme, causing irreversible inhibition (Anderson et al., 1999). Using chlorofluoroacetate as a substrate, Lanthum et al., (2002) found that, after inhibition, the 1a-1a variant retained 12% of its initial activity where as the 1b-1b, 1c-1c and 1d-1d variants retained only 3-5% of their original activity.

## **5. EFFECTS ON HUMANS**

Paragraph 1

Dichloroacetic acid has been used as a therapeutic agent to treat lactic acidosis, diabetes, and familial hyperlipidemia in humans; oral or intravenous therapeutic doses are usually in the range of 25-50 mg/kg of body weight per day (Stacpoole et al., 1998a). Biochemical effects of dichloroacetate treatment include significantly-reduced fasting blood glucose levels; marked decreases in plasma lactate and alanine; significantly-decreased plasma cholesterol levels; decreased triglyceride levels; elevated plasma ketone bodies; and elevated serum uric acid levels (Stacpoole et al., 1978). Approximately 50% of patients receiving 25-50 mg/kg of body weight

---

per day experience anxiolytic or sedative effects following oral, intravenous, or repeated dosing regimens. These effects usually occur within 60 minutes of dichloroacetic acid treatment, may last several hours, and appear to be unrelated to gender, age, or route of administration (Stacpoole et al., 1998a).

#### Paragraph 2

Several cases of mild peripheral neuropathy following dichloroacetic acid treatment of 50–100 mg/kg of body weight per day for several months to a year have been reported (Stacpoole et al, 1998a; Spruijt et al., 2001). All were completely reversible after cessation of treatment. In one of these cases, dichloroacetic acid was reinstated at 25 mg/kg of body weight per day following reversal of neurological symptoms, and this dose was maintained for 2 years without further evidence of neuropathy (Stacpoole et al., 1998a). Two children with congenital lactic acidosis were treated with 25–75 mg/kg body weight per day oral dichloroacetic acid for several months; they showed a twofold increase in serum transaminases, suggesting the possibility of preclinical hepatic toxicity. This increase was reversible after treatment ended (Stacpoole et al., 1998a).

#### Paragraph 3

Two young males were administered daily oral doses of 50 mg of dichloroacetate per kg of body weight to treat severe familial hypercholesterolaemia. Total serum cholesterol levels decreased significantly in both patients (Moore et al., 1979). No adverse clinical or laboratory symptoms were detected in one patient, but the second complained of tingling in his fingers and toes after 16 weeks. Physical examination revealed slight decreases in the strength of facial and finger muscles, diminished to absent tendon reflexes, and decreased strength in all muscle groups of the lower extremities. Electromyographic studies showed denervation changes in foot and leg muscles. Mild slowing of conduction velocity was noted in both posterior tibial nerves, and no measurable response was obtained in the peroneal or orbital nerves. Six months after discontinuation of the treatment, the observed peripheral neuropathy had improved, although serum cholesterol returned to high levels (Stacpoole et al., 1979).

#### Paragraph 4

To date, there have been no reports of dichloroacetic acid-induced neoplasia in any human tissue and no reports of gonadal toxicity in humans (Stacpoole et al., 1998a). However, dichloroacetic acid is presently only being used in the treatment of lactic acidosis and mortality among this population is high, at about 20 % per year (Stacpoole et al, 1998b), providing a limited opportunity to observe the effects of chronic exposures.

## **6. EFFECTS ON LABORATORY ANIMALS AND *IN VITRO* TEST SYSTEMS**

### **6.1 Acute exposure**

#### Paragraph 1

---

Oral LD<sub>50</sub>s of 4480 and 5520 mg of dichloroacetic acid per kg of body weight have been reported in rats and mice, respectively (Woodard et al., 1941). Acute effects included narcosis, with either death or complete recovery within 36 hours. In another study on male rats, the LD<sub>50</sub> was 2820 mg/kg, and the dermal LD<sub>50</sub> was 0.1 ml/kg (about 795 mg/kg) (Smyth et al., 1951). Groups of Long-Evans rats (10 per group) administered a single gavage dose of 0, 300, 1000, or 2000 mg/kg of body weight of dichloroacetic acid exhibited neurobehavioral toxicity 4–24 hours following dosing, as indicated by decreased hind-limb grip strength and decreased motor activity. Based on decreased grip strength, the lowest dose of 300 mg/kg of body weight was a LOAEL (Moser et al., 1999). These effects were reversible, with recovery occurring 7–14 days after dosing.

### 6.2.2 Short-term exposure

#### Paragraph 1

Increased liver weight and localized areas of liver necrosis were reported in male B6C3F1 and male and female Swiss-Webster mice treated with dichloroacetic acid in drinking-water for 14 days at concentrations of 1 or 2 g/litre (250 or 500 mg/kg of body weight per day); male B6C3F1 mice were also treated with 0.3 g/litre (75 mg/kg of body weight per day), and no effects on the liver were observed at this dose. Increased cell proliferation in the livers of male B6C3F1 mice occurred at 2 g/litre (500 mg/kg of body weight per day) after 5 but not 14 days (Sanchez & Bull, 1990).

#### Paragraph 2

Male B6C3F1 mice given dichloroacetic acid in drinking-water at concentrations of 0 or 0.1 to 3 g/litre (0 or 16 to 490 mg/kg of body weight per day) for up to 8 weeks showed significant dose-dependent increases in the glycogen content of the liver at concentrations of 0.5 g/litre (approximately 80 mg/kg of body weight per day) and higher (Kato-Weinstein et al., 1998).

#### Paragraph 3

Sprague-Dawley rats (10 per sex per dose) were administered sodium dichloroacetate by gavage at dose levels of 0, 125, 500, or 2000 mg/kg of body weight per day for 3 months. Two rats of each sex in the 2000 mg/kg/day group died during the study. The major signs of intoxication were hind limb paralysis and frequent urination. Effects included a dose-dependent decrease in body weight, and increased relative weights of liver, kidneys, and adrenals at all dose levels. Brain and testes were the principal target organs; brain lesions, characterized by vacuolation of the myelinated white tracts resembling oedema, were observed in the cerebrum and cerebellum of treated rats of both sexes in all dose groups. Based on organ weight effects and brain lesions, the lowest dose tested, 125 mg/kg of body weight per day, was identified as a LOAEL (Katz et al., 1978; 1981).

#### Paragraph 4

---

Beagle dogs were given sodium dichloroacetate by capsule at 50, 75, or 100 mg/kg of body weight per day for 13 weeks. Effects included dose-dependent weight losses, a progressive depression in haematologic parameters, and decreased mean blood glucose, lactate, and pyruvate levels at all dose levels. Histopathologic effects included slight to moderate vacuolation of white myelinated tracts in the cerebrum and, to a lesser extent, in the cerebellum; an increased incidence of haemosiderin-laden Kupffer's cells in the liver and cystic mucosal hyperplasia in the gall bladder were observed at all dose levels. In this study, the lowest dose tested, 50 mg/kg of body weight per day, was the LOAEL (Katz et al., 1978, 1981).

#### Paragraph 5

Beagle dogs (5 per sex per dose) received dichloroacetate in capsules at daily doses of 0, 12.5, 39.5, or 72 mg/kg of body weight per day for 90 days. At 72 mg/kg of body weight per day, effects included dyspnoea and partial paralysis of the hind limbs, and decreased erythrocyte count and hemoglobin levels. At 39.5 mg/kg of body weight per day and above, effects included decreased body weight gain in both sexes. At 12.5 mg/kg of body weight per day and above, effects included increased relative liver weights in males, conjunctivitis, and histopathology in the liver, kidney, pancreas, brain, and testes. Lesions included pale and discolored kidneys; mild vacuolar change, inflammation, and haemosiderosis in the liver; chronic inflammation and acinar degeneration in the pancreas; mild vacuolization of white myelinated tracts in the cerebrum and/or cerebellum; and testicular abnormalities. The LOAEL for this study was 12.5 mg/kg of body weight per day, the lowest dose tested (Cicmanec et al., 1991).

#### Paragraph 6

The neurobehavioral toxicity of dichloroacetic acid was examined in two age groups of rats (young adult and weanling), using two strains of rats (F344 and Long-Evans) and two routes of administration (drinking-water and gavage) for varying lengths of time (8 weeks to 24 months). Daily doses of dichloroacetic acid ranged from 16 to 308 mg/kg of body weight per day for drinking-water exposures and 30 to 1000 mg/kg of body weight per day for gavage exposures. Gait abnormalities, described as uncoordinated placement of the hind limbs and hunched posture, were observed at daily doses as low as 16 mg/kg of body weight. At higher doses, other effects observed in both F344 and Long-Evans rats included deficits in the righting reflex, decreased hind limb grip strength, and mild tremors; ocular abnormalities and a unique chest-clasping response were observed only in F344 rats. The neurotoxicity was progressive with continued exposure and persisted for up to 2 years following high-dose exposures of 6 months. The neurotoxicity was most severe in F344 rats whose exposure in drinking-water began post-weaning. In general, F344 rats were more sensitive than Long-Evans rats, and weanlings appeared to be somewhat more sensitive than young adults. Histopathology showed that microscopic effects were limited to the central nervous system and were most severe in the spinal cord, which showed degeneration of the posterior columns accompanied by gliosis and loss of myelinated axons. Based on gait abnormalities in drinking-water studies of 12-13 weeks duration, the LOAEL was 16 mg/kg of body weight per day, the lowest dose tested (Moser et al., 1999).

### 6.2.3 Long-term exposure

#### Paragraph 1

Male F3344 rats (60–78 per group) were given dichloroacetic acid in drinking-water at concentrations of 0, 0.05, 0.5, or 5.0 g/litre for 100 weeks. Time-weighted average daily doses in the control, low, and middle dose groups were 0, 3.6, or 40.2 mg/kg of body weight, respectively, over the course of 100 weeks of treatment. In the high dose group, early signs of peripheral neuropathy resulted in a sequential lowering of the drinking-water concentrations to 1.0 g/litre at 52 weeks. The neuropathy did not reverse or diminish, and as a result, the animals were sacrificed at 60 weeks; the results of this dose group were excluded from the analysis. There was a mild increase in absolute and relative testis weights at 40.2 mg/kg of body weight per day. No liver necrosis was noted in any of the groups (DeAngelo et al., 1996). In a second study using the same experimental protocol, male F344 rats (78 per group) were given 0 or 2.5 g/litre of dichloroacetic acid in drinking-water. Peripheral neuropathy in the treated group resulted in a sequential lowering of dichloroacetic acid concentrations to 1.0 g/litre at 26 weeks. Treatment at this level was continued to 103 weeks. The time-weighted average daily dose was 139 mg/kg of body weight. Final mean body weights of treated animals was significantly reduced to 73% of control values. Absolute testes weights were significantly decreased, but there was no change in relative testes weights. Neither changes in other organ weights nor non-neoplastic liver lesions were observed at final sacrifice (DeAngelo et al., 1996).

#### Paragraph 2

Male B6C3F1 mice (30–71 per dose group) were administered dichloroacetic acid in drinking-water at concentrations of 0, 0.05, 0.5, 1, 2, or 3.5 g/litre (0, 8, 84, 168, 315, or 429 mg/kg per body weight per day) for 90-100 weeks. A dose-dependent increase in liver weight was seen at 26 and 52 weeks in all treatment groups evaluated for this endpoint (84 mg/kg of body weight per day and higher) but only at the two highest dose levels at 100 weeks. At final sacrifice, mean body weights were significantly decreased, and absolute and relative liver weights were significantly increased at 315 mg/kg of body weight per day and higher. A dose-dependent increase in liver toxicity, as indicated by a significant increase in alanine aminotransferase and liver necrosis was observed at a dose of 168 mg/kg of body weight per day and higher; significantly increased alanine aminotransferase activity was also observed with the 84 mg/kg of body weight per day dose. Hepatic peroxisome proliferation was increased in the high-dose group (DeAngelo et al., 1999).

#### Paragraph 3

Male B6C3F1 mice (50 per dose group) received dichloroacetate in their drinking-water at 0, 0.05, 0.5, 3.5, or 5.0 g/litre (0, 7.6, 77, 410, or 486 mg/kg of body weight per day) for 60 weeks. Other groups of mice received dichloroacetate at 7.6 or 77 mg/kg of body weight per day for 75 weeks. In the highest-dose group, water consumption was reduced to 60% of that of controls. Body weight was decreased at the two highest dose levels, and relative liver weight was

---

increased at the three highest dose levels. An increase in kidney weight was seen only at 410 mg/kg of body weight per day. No effects were seen on testes or spleen weight. The NOAEL for the 60- and 75-week studies was 7.6 mg/kg of body weight per day (DeAngelo et al., 1991).

#### **6.2.4 Reproductive and developmental toxicity**

##### Paragraph 1

Male Sprague-Dawley rats (8 per group) were given dichloroacetic acid by gavage at doses of 0, 18, 54, 160, 480, or 1440 mg/kg of body weight per day for 14 days and evaluated for reproductive tract toxicity. At 480 mg/kg of body weight per day and higher, epididymis weights were decreased. At 160 mg/kg of body weight per day and higher, the percentage of abnormal cauda sperm was significantly increased, and there was a statistically significant decrease in the percent motile sperm. At 54 mg/kg of body weight per day and higher, rats exhibited clear histopathologic effects on spermiation indicative of spermatotoxicity, which increased in severity with increasing dose. Effects included altered spermiation, including retention of Step 19 spermatids, and atypical formation and resorption of residual bodies. At 18 mg/kg of body weight per day, two animals were judged by the authors to have mild increased retention of Step 19 spermatids; however, the statistical significance of this finding was not reported, and no data on control responses were given. Based on these results, 18 mg/kg of body weight per day was identified as a NOAEL (Linder et al., 1997).

##### Paragraph 2

Pregnant Long-Evans rats (20 per group) received dichloroacetic acid by oral gavage on gestation days 6-15 at doses of 0, 900, 1400, 1900, or 2400 mg/kg of body weight per day (first study) or 0, 14, 140 or 400 mg/kg of body weight per day (second study). At 1400 mg/kg of body weight per day and higher, dose-related mortality occurred in treated dams. At 140 mg/kg of body weight per day and higher, maternal body weight gain was significantly reduced. Significant dose-related increases in the relative liver weights of the dams were observed at all dose levels. At 900 mg/kg of body weight per day and above, post-implantation losses were significantly increased, and the number of live fetuses per litter was significantly reduced. No treatment-related effects were observed for pregnancy rates, the total number of implants per litter, or the frequency of pre-implantation losses. Dose-related decreases in fetal growth and increases in total soft tissue malformations occurred at 140 mg/kg of body weight per day and above. In this study, the maternal and developmental NOAELs were both 14 mg/kg of body weight per day. This was based on increased relative maternal liver weight, and increased soft tissue abnormalities at 140 mg/kg of body weight per day (Smith et al., 1992).

##### Paragraph 3

Pregnant rats were administered gavage doses of dichloroacetate ranging from 1900 to 3500 mg/kg of body weight per day, on specific 1-3 day periods during gestation in order to examine the effects of treatment during organogenesis. Reduced fetal body weight was observed in the offspring of dams exposed to 1900 mg/kg body weight on gestation days 6-8. Fetal cardiac

---

malformations were reported in the offspring of pregnant dams dosed at 1900 mg/kg of body weight per day on gestation days 9–11 and 12–15, at 2400 mg/kg of body weight per day on gestation days 10 or 12, and at 3500 mg/kg of body weight per day on gestation day 12 (Epstein et al., 1992). Collectively, these studies indicate a developmental LOAEL of 1900 mg/kg body weight per day.

Paragraph 4

Saillenfait et al., 1995 studied groups of 10 to 20 explanted embryos from Sprague-Dawley rats cultured for 46 h in DCA solutions (0–10 mmol/litre). A significant, dose-dependent decrease in crown rump length was seen at 3.5 mmol/litre and above, while significant, dose-related decreases in yolk sac diameter, head length, somite (embryonic segment) number, protein content, and DNA content were seen at 2.5 mmol/litre and above. In addition, several structural defects not seen in the control or lowest dose group were increased at the higher doses. Data for teratogenicity of dichloroacetic acid were considered to be equivocal in the frog embryo teratogenesis assay - *Xenopus* (FETAX) (Bantle et al., 1999).

### 6.2.5 Genotoxicity and related end-points

Paragraph 1

There have been numerous studies investigating the genotoxicity of dichloroacetic acid (summarized in US EPA, 2003). The results of most *in vitro* tests have been negative or equivocal, with or without metabolic activation. For example, negative or equivocal results were obtained in most reverse mutation tests in *Salmonella typhimurium*, tests for DNA strand breakage in mammalian cells, and in most forward mutation tests in mouse lymphoma cells. One report indicated that dichloroacetic acid may increase prophage induction in *E. coli* (DeMarini et al., 1994); this finding has not been confirmed by other laboratories, and required extremely high dichloroacetic acid concentrations to achieve significance. The results of *in vivo* studies have been mixed. No consistent pattern of positive or negative results for genotoxicity has been observed in the mouse micronucleus assay, or in assays for DNA strand breaks in mouse or rat cells or for DNA adduct formation (Austin et al., 1996; Parrish et al., 1996; US EPA, 2003). Dichloroacetic acid was reported to induce both gene mutations and gross chromosomal aberrations in L5178Y mouse lymphoma cells *in vitro*, but the concentrations required to induce these effects were in the millimolar range (Harrington-Brock et al., 1998).

Paragraph 2

Transgenic mice (Big Blue) were exposed to dichloroacetic acid in drinking-water at concentrations of 1 or 3.5 g/litre (approximately 190 or 665 mg/kg of body weight per day) for 60 weeks. After 4 or 10 weeks of treatment, neither concentration induced an increased frequency of mutations in the *lacI* gene; after 60 weeks, both concentrations induced a significantly elevated mutational frequency at this locus. In order to account for possible confounding by clonal expansion, the type of mutation (i.e. base substitutions) was analyzed, and duplicate identical mutations in each animals were subtracted from the total number of

---

mutations. Mutational frequencies in the lacI gene still differed significantly between treated and control mice after this adjustment (Leavitt et al., 1997).

### 6.2.6 Carcinogenicity

#### Paragraph 1

Male B6C3F1 mice were given dichloroacetic acid in drinking-water at 0 or 5 g/litre (approximately 0 or 1000 mg/kg of body weight per day) for 61 weeks. An increase in hepatocellular carcinomas was observed in 81% of treated animals (Herren-Freund et al., 1987).

#### Paragraph 2

Male B6C3F1 mice receiving 2 g/litre (300 mg/kg of body weight per day) of dichloroacetic acid in drinking-water for 52 weeks developed hepatocellular carcinomas; tumours were not observed in male mice administered 1 g/litre (140 mg/kg of body weight per day) for 52 weeks, or given 2 g/litre (280 mg/kg of body weight per day) for 37 weeks followed by a 15-week recovery period. (Bull et al., 1990).

#### Paragraph 3

Male B6C3F1 mice given dichloroacetic acid in drinking-water at a concentration of 0 or 0.5 g/litre (0 or 88 mg/kg of body weight per day) for 104 weeks developed hepatocellular carcinomas in 63% of treated animals as compared with 10% in controls; hepatocellular adenomas in 42% of treated animals as compared with 5% in controls; and hyperplastic nodules in 8% in treated animals as compared with 0% in controls (Daniel et al., 1992).

#### Paragraph 4

Male B6C3F1 mice were administered dichloroacetic acid in drinking-water at concentrations of 0, 0.05, 0.5, 3.5, or 5.0 g/litre (0, 7.6, 77, 410, or 486 mg/kg of body weight per day) for 60 weeks. An increase in liver adenomas, carcinomas, and hyperplastic nodules was observed only in the two highest dose groups (DeAngelo et al., 1991).

#### Paragraph 5

Male B6C3F1 mice (35–71 per dose) were given dichloroacetic acid in drinking-water at concentrations of 0, 0.05, 0.5, 1.0, 2.0, or 3.5 g/litre (0, 8, 84, 168, 315, or 429 mg/kg of body weight per day, based on measured water consumption) for 90-100 weeks. Interim sacrifices were conducted at 26, 52, and 78 weeks in all dose groups except the lowest one. No hepatocellular tumours were observed in any group after 26 weeks of exposure. At 52 weeks, the incidence of hepatocellular carcinoma was significantly elevated in the two highest dose groups (20% and 50% of animals in the 2.0 and 3.5 g/litre groups, respectively, versus 0% in controls). At 78 weeks, the percentage of animals with this tumour had increased to 50% and 70% in the 2.0 and 3.5 g/litre groups, respectively, compared with a control rate of 10%. At study

---

termination, the incidence of hepatocellular carcinoma was significantly elevated in the three highest dose groups, with 71%, 95%, and 100% of the animals, respectively, developing these tumours, compared with 26% of controls. Hepatic peroxisome proliferation (as measured by cyanide-insensitive palmitoyl coenzyme A oxidase) was significantly elevated only in the highest dose group after 26 weeks of exposure, and was not increased at any time point in other dose groups. Hepatocyte proliferation (as measured by incorporation of radiolabelled thymidine) outside of proliferative lesions was not significantly different from control rates at any of the doses that produced tumours. The authors concluded that neither peroxisome proliferation nor hepatocyte proliferation was associated with the induction of liver cancer in these mice (DeAngelo et al., 1999).

Paragraph 6

Carter et al., (2003) examined the histology slides from the DeAngelo et al (1999) study. The slides were examined independently by two individuals for the presence of altered hepatic foci, large foci of cellular alteration, adenomas and carcinomas. The investigators were blind to the dose and time of sacrifice of the animals. Lesions were subcategorized as eosinophilic, dysplastic, and basophilic and/or clear cell. After all of the slides were characterized they were arrayed by dose and time-of sacrifice to determine if there was a pattern in the progression to tumours. Several separate patterns were observed. Eosinophilic cells seemed to progress from altered hepatic foci to eosinophilic adenomas and carcinomas. Basophilic or clear cells either progressed from altered hepatic foci to large foci of cellular alteration to carcinomas or from large foci of cellular alteration to adenomas and carcinomas. Dysplastic cells progressed from altered hepatic foci to carcinomas.

In this same study the tissues were also examined for the relationship between necrosis, glycogen accumulation, cytomegaly, accumulation of lipid droplets, atypical nuclei and enlarged nuclei and tumours . The strongest dose–response correlation was noted for cytomegaly and to a lesser extent for atypical nuclei

Paragraph 7

Female B6C3F1 mice administered 2.0 g/litre (300 mg/kg of body weight per day) of dichloroacetic acid in drinking-water for 52 weeks did not develop liver tumours (Bull et al., 1990). On the other hand, Female B6C3F1 mice were given dichloroacetic acid in drinking-water at concentrations of 0, 0.5, or 3.5 g/litre (0, 77, or 410 mg/kg of body weight per day) for 104 weeks. Liver tumours were observed in all animals in the highest dose group (US EPA, 1991).

Paragraph 8

Female mice (40-90 per dose) were administered dichloroacetic acid in drinking-water at concentrations of 0, 0.26, 0.86, or 2.6 g/litre (reported to be 0, 40, 115, or 330 mg/kg of body weight per day) for 51 or 82 weeks. Increased incidences of adenomas and altered hepatocyte foci were observed in the highest dose group after 51 weeks, and in the two highest dose groups

---

after 82 weeks. After 51 weeks at 330 mg/kg of body weight per day, 40% of animals exhibited altered foci and 35% had adenomas. After 82 weeks at 115 mg/kg of body weight per day, 39.3% of animals at the mid dose showed altered foci, and 25% had developed liver adenomas; after 82 weeks at 330 mg/kg of body weight per day, 89.5% of the animals had altered hepatocyte foci and 84.2% had adenomas. A statistically significant increase in the percent of animals with liver carcinoma (26.3%) was observed only in the high-dose group after 82 weeks of exposure. The total yield of lesions (altered hepatocyte foci, hepatocellular adenomas, or hepatocellular carcinomas) was statistically increased in the high-dose group at 51 weeks (40% compared with 0% in controls) and in the mid- and high-dose groups at 82 weeks (39.3% in mid-dose group, 89.5% in high-dose group, compared with 11.1% in controls). The dose–response relationship between drinking-water concentrations of dichloroacetic acid and the yield of liver tumours and altered hepatocyte foci was described by the author as being suggestive of non-linearity (Pereira, 1996).

#### Paragraph 9

Male F344 rats (60-78 per group) were given dichloroacetic acid in drinking-water at concentrations of 0, 0.05, 0.5, or 5.0 g/litre. Animals in the highest dose group developed early signs of peripheral neuropathy that were not reversed or diminished by a sequential lowering of the drinking-water concentration of dichloroacetic acid; these animals were sacrificed at 60 weeks and the results of this dose group were excluded from the analysis. Time-weighted average daily doses in the remaining groups were 0, 3.6, or 40.2 mg/kg of body weight over the course of 100 weeks of treatment. At 40.2 mg/kg of body weight per day, the incidence of combined hepatocellular adenomas and carcinomas was 24.1% in treated animals as compared with 4.4% in controls. Total proliferative lesions (combined neoplasms and hyperplastic nodules) were observed in 34.9% of animals in this dose group as compared with 8.7% of controls. No liver histopathology was observed at 3.6 mg/kg of body weight per day (DeAngelo et al., 1996). In a second study using the same experimental protocol, male F344 rats (78 per group) were given drinking-water containing dichloroacetic acid at concentrations of 0 or 2.5 g/litre. Peripheral neuropathy in the treated group resulted in a sequential lowering of dichloroacetic acid concentrations to 1.0 g/litre at 26 weeks, and treatment was continued to 103 weeks. The time-weighted average doses were 0 or 139 mg/kg of body weight per day. Hepatocellular carcinomas were observed in 21.4% in treated animals compared with 3% in controls; combined hepatocellular adenomas and carcinomas were found in 28.6% of treated animals as compared with 3.0% of controls. Proliferative lesions were observed in 32.1% of treated animals, compared with 6.1% in controls (DeAngelo et al., 1996).

#### Paragraph 10

A number of mechanistic bioassays have shown that altered hepatic foci and hepatocellular tumours initiated or promoted by treatment with dichloroacetic acid are eosinophilic and contain glutathione S-transferase-pi (Pereira & Phelps, 1996). Altered hepatic foci and hepatocellular tumours exhibit differences in the mutational spectra of K- and H-ras proto-oncogenes, as compared with spontaneously-occurring tumours (Anna et al., 1994; Ferreira-Gonzales et al.,

---

1995), do not show loss of heterozygosity on chromosome 6 (Tao et al., 1996), and selectively stimulate the replication rate of different populations of immunoreactive cells (Stauber & Bull, 1997; Latendresse & Pereira, 1997).

Paragraph 11

There are two reports of gene array analysis of liver cells from mice treated with 2 g/litre dichloroacetic acid for 4 weeks.(Thai et al., 2001; 2003). Both reports involve the same tissue samples. The three different gene arrays tested displayed differences between control tissues and those from exposed mice. Not all of genes affected were identified. Those that were affected fell into three groupings according to the authors: genes involved with tissue remodeling and/or angiogenesis, damage response, and xenobiotic metabolism. In most cases gene expression was suppressed. The PPAR-alpha gene was present on one of the gene arrays and was not found to be activated by the dose of dichloroacetic acid used.

Paragraph 12

The information available on the mechanisms of dichloroacetic acid-induced liver tumourigenesis in rodents is not sufficient to identify a single mode of action leading to cancer. It is possible that multiple mechanistic pathways are involved in DCA-induced rodent hepatocarcinogenicity, and that these pathways are dose-dependent or species-specific.

## 7. GUIDELINE VALUE

Paragraph 1

US EPA has classified dichloroacetic acid as B2, probable human carcinogen (US EPA, 1998) in accordance with the 1986 EPA *Guidelines for Carcinogen Risk Assessment* (US EPA, 1986); and *likely to be carcinogenic in humans* (US EPA, 2003) in accordance with the 1999 EPA *Proposed Guidelines for Carcinogen Risk Assessment* (US EPA, 1999). IARC has recently reclassified dichloroacetic acid as Group 2B, *possibly carcinogenic to humans* in the absence of data on human carcinogenicity and on the basis of *sufficient evidence* of its carcinogenicity in experimental animals (IARC, 2002). These classifications were based primarily on findings of liver tumours in rats (DeAngelo et al., 1996; Richmond et al., 1995) and mice (Bull et al., 1990; Daniel et al., 1992; Herren-Freund et al., 1987; Pereira, 1996; Pereira and Phelps, 1996; DeAngelo et al., 1999).

Paragraph 2

Available data are not sufficient to establish a cancer mode of action with reasonable certainty, especially at the very low exposure levels expected to apply to humans ingesting chlorinated drinking-water. Although there are a number of studies that provide some information on the mode(s) of action by which dichloroacetic acid may increase cancer incidence in animals, sufficient data are not available to conclusively identify a single mode of action as the only or most important pathway leading to carcinogenesis. Further, the possibility exists that different

---

modes may be acting in different species, or even in the same species at different doses. The number of metabolic pathways and species differences in metabolism are still not known, nor has the ultimate toxic substance been identified. Genotoxicity data are considered to be inconclusive, particularly at lower doses.

#### Paragraph 3

The tumour prevalence data from male mice (DeAngelo et al., 1999) were used to quantify the cancer risk from dichloroacetic acid. The point of departure (POD) selected for the quantification of cancer risk is the lower-bound confidence limit on the benchmark dose (BMDL) of 2.1 mg/kg/day, derived from the fit of the multi-stage model using US EPA's Benchmark Dose software (version 1.3.1) and human equivalent doses from the DeAngelo et al. (1999) study.

In the absence of causal mode of action data at environmentally relevant exposures, and in accordance with USEPA's Proposed Carcinogen Assessment Guidelines (US EPA, 1999), extrapolation from the POD to low dose was performed by assuming a linear dose-response curve between the POD and the origin. Based on the data from the DeAngelo (1999) study, the slope factor for dichloroacetic acid is  $0.007 \text{ (mg/kg per day)}^{-1}$ . (This slope factor does not include a body weight correction.)

#### Paragraph 4

Assuming a 60-kg person ingesting 2 litres of water per day, the concentration of dichloroacetic acid in drinking-water associated with upper-bound excess lifetime cancer risks of  $10^{-4}$ ,  $10^{-5}$  and  $10^{-6}$  are 400, 40 and 4 µg/litre, respectively. The concentration associated with a  $10^{-5}$  cancer risk is 40 µg/litre and is usually identified as the health-based guideline for drinking-water when the contaminant is a carcinogen. However, it may not be possible to provide for adequate disinfection treatment of potable water and maintain dichloroacetic acid levels of less than or equal to 40 µg/litre. Accordingly, the guideline value is provisionally established as 50 µg/litre. The guideline value is designated as provisional because the data on treatment achievability are insufficient to ensure that the 40 µg/litre value is technically achievable under a wide range of circumstances. Difficulties in meeting a guideline value must never be a reason to compromise adequate disinfection.

## **8. ANALYTICAL ACHIEVABILITY OF THE PROVISIONAL GUIDELINE**

#### Paragraph 1

The PQL in EPA Methods 552.1 and 552.2 and Standard Method 6251B is approximately 1 µg/litre for dichloroacetic acid. Accordingly, the provisional guideline value for dichloroacetic acid is above the achievability of the analytical methods.

## **9. TREATMENT ACHIEVABILITY OF THE PROVISIONAL GUIDELINE**

#### Paragraph 1

It should be possible to achieve a dichloroacetic acid concentrations at or below the 50 µg/litre provisional guideline value by appropriate control of the water treatment process. Controlling coagulation to remove organic carbon prior to chlorination can reduce dichloroacetic acid concentrations. Increasing the coagulant dose can give enhanced removal of organic precursors (Hartman *et al.* 1991); however, the pH needs to be controlled otherwise the lower pH associated with higher coagulant doses can lead to increased dichloroacetic acid concentrations (Dixon and Lee 1991). Some control of dichloroacetic acid concentrations can be achieved by increasing the pH at which chlorination is carried out but this may lead to increased formation of THMs (Singer *et al.* 1995, Nikolaou *et al.* 1999).

Paragraph 3

Lower dichloroacetic acid concentrations can be achieved by using alternatives to chlorine for disinfection. Plants using ozone followed by chloramine were found to produce lower dichloroacetic acid concentrations than those using free chlorine (Nissinen *et al.* 2002).

Paragraph 4

Granular activated carbon can be used to obtain greater than 80% removal of dichloroacetic acid (Lykins *et al.* 1991); however, removal of dichloroacetic acid once formed is unlikely to be the preferred method of control.

## 9. REFERENCES

Anderson, WB; Board, PG; Gargano, B; et al. Inactivation of glutathione transferase zeta by dichloroacetic acid and other fluorine-lacking  $\alpha$ -haloalkanoic acids. *Chemical Research Toxicology*, 1999, 12:1144-1149.

Anna CR, Maronpot M, Pereira J, Foley DM, Anderson M. Proto-oncogene activation in dichloroacetic acid-, trichloroethylene- and tetrachloroethylene- induced liver tumors in B6C3F1 mice. *Environmental Carcinogenesis Program, National Institute of Environmental Health Sciences*. 1994, pp. 2255-2261.

APHA. American Public Health Association. *Standard methods for the examination of water and wastewater*, 20<sup>th</sup> Edition, 1998, Washington, DC. American Public Health Association/American Water Works Association/Water Pollution Control Federation.

Austin EW, Parrish JM, Kinder DH, Bull RJ. Lipid peroxidation and formation of 8-hydroxydeoxyguanosine from acute doses of halogenated acetic acids. *Fundamental and applied toxicology*, 1996, 31:77-82.

Bantle JA, Finch RA, Fort DJ, Stover EL, Hull M, Kumsher-King M, Gaudet-Hull AM. Phase III Interlaboratory Study of FETAX Part 3. FETAX validation using 12 compounds with and without an exogenous metabolic activation system. *Journal of applied toxicology*, 1999, 19: 447-472.

Blackburn, AC; Coggan, M; Tzeng, H-F; et al. GSTZ1d: a new allele of glutathione transferase zeta and maleylacetoacetate isomerase. *Pharmacogenetics*, 2001, 11:671-678.

Budavari S, O'Neill M, Smith A, eds. *The Merck Index. An encyclopedia of chemicals, drugs, and biologicals*, 1989, 11<sup>th</sup> ed. Rahway, NJ, Merck.

---

Bull RJ, Sanchez IM, Nelson MA, Larson JL, Lansing AJ. Liver tumor induction in B6C3F<sub>1</sub> mice by dichloroacetate and trichloroacetate. *Toxicology*, 1990, 63:341-359.

Carter, JH; Carter, HW; Deddens, JA; et al. A 2-year dose-response study of lesion sequences during hepatocellular carcinogenesis in the male B6C3F<sub>1</sub> mouse given the drinking water chemical dichloroacetic acid. *Environ Health Perspectives*, 2003, 111:53-64.

Cicmanec JL, Condie LW, Olson GR, Wang SR. 90-Day toxicity study of dichloroacetate in dogs. *Fundamental and applied toxicology*, 1991, 17(2): 376-89.

Clemens M & Scholer HF. Halogenated organic compounds in swimming pool waters. *Zentralbl. Hyg. Umweltmed*, 1992, 193(1):91-98.

Cornett R, James M, Henderson G, Cheung J, Shroads A, Stacpoole P. Inhibition of glutathione S-transferase and tyrosine metabolism by dichloroacetate: A potential unifying mechanism for its altered biotransformation and toxicity. *Biochemical and biophysical research communications*, 1999, 262:752-756.

Curry, SH; Chu, PI; Baumgartner, TG; et al. Plasma concentrations and metabolic effects of intravenous sodium dichloroacetate. *Clin Pharmacol Therap*, 1985, 37:89-93.

Daniel FB, DeAngelo AB, Stober JA, Olson GR, Page NP. Hepatocarcinogenicity of chloral hydrate, 2-chloroacetaldehyde, and dichloroacetic acid in the male B6C3F<sub>1</sub> mouse. *Fundamental and applied toxicology*, 1992, 19(2):159-168.

DeAngelo AB, George MH, House DE. Hepatocarcinogenicity in the male B6C3F<sub>1</sub> mouse following a lifetime exposure to dichloroacetic acid in the drinking water: dose-response determination and modes of action. *Journal of toxicology and environmental health*, 1999, 58(8):485-507.

DeAngelo AB, Daniel FB, Most BM, Olsen GR. The carcinogenicity of dichloroacetic acid in the male Fischer 344 rat. *Toxicology*, 1996, 114:207-221.

DeAngelo AB, Daniel FB, Stober JA, Olson GR. The carcinogenicity of dichloroacetic acid in the male B6C3F<sub>1</sub> mouse. *Fundamental and applied toxicology*, 1991, 16:337-347.

DeMarini DM, Perry EP, Sheldon ML. Dichloroacetic acid and related compounds: Induction of prophage in *E. coli* and mutagenicity and mutation spectra in *Salmonella* TA 100. *Mutagenesis*, 1994, 9: 429-437.

Dixon, K.L. and Lee, R.G. (1991) Disinfection by-products control: a survey of American system treatment plants. Proceedings of the 1991 Annual Conference of the American Water Works Association, Water Research for the New Decade, 265-285.

Epstein DL, Nolen GA, Randall JL, Christ SA, Read EJ, Stober JA, Smith ML. Cardiopathic effects of dichloroacetate in the fetal Long-Evans rat. *Teratology*, 1992, 4693:225-235.

Evans OB. Dichloroacetate tissue concentration and its relationship to hypolactatemia and pyruvate dehydrogenase activity by dichloroacetate. *Biochemical pharmacology*, 1982. 31:3124-3126.

Fernandez-Canon, JM; Penalva, MA. Characterization of a fungal maleylacetoacetate isomerase gene and identification of its human homologue. *J Biol Chem*, 1998, 273:329-327.

Ferreira-Gonzalez A, DeAngelo AB, Nasim S, Garrett TC. Ras oncogene activation during hepatocarcinogenesis in B6C3F<sub>1</sub> male mice by dichloroacetic and trichloroacetic acids. *Carcinogenesis*, 1995, 16(3): 495-500.

---

Gonzalez-Leon A, Schultz IR, Xu G, Bull JR. Pharmacokinetics and metabolism of DCA in the F344 rat after prior administration in drinking. *Toxicology and applied pharmacology*, 1997, 146:189-95.

Harrington-Brock, K; Doerr, CL; Moore, MM. (1998) Mutagenicity of three disinfection by-products; di- and trichloroacetic acid and chloral hydrate in L5178Y/TK +/- 3.7.2C mouse lymphoma cells. *Mutat Res* 413:265-276.

Hartman, D.J., DeMarco, J., Metz, D.H., Himmelstein, K.W. and Miller, R. (1991) Controlling by-products precursor removal by GAC and alum coagulation. Proceedings of the 1991 American Water Works Association Annual Conference, Water Research for the New Decade, 193-252.

Hawley GG. *The Condensed Chemical Dictionary*, 10<sup>th</sup> ed. 1981, New York, NY, Van Nostrand Reinhold, 241.

Herren-Freund SL, Pereira MA, Khoury MD, Olson G. The carcinogenicity of trichloroethylene and its metabolites, trichloroacetic acid and dichloroacetic acid, in mouse liver. *Toxicology and applied pharmacology*, 1987, 90:183-189.

HSDB Database. <http://www.toxnet.com>. Hazardous Substance Data HSDB Database. Accessed 2001.

IARC. International Agency for Research on Cancer. Dry cleaning, some chlorinated solvents and other industrial chemicals. Lyon, International Agency for Research on Cancer 1995, (IARC *Monographs on the Evaluation of Carcinogenic Risks to Humans*, Volume 63).

IARC. International Agency for Research on Cancer. Some Drinking-water Disinfectants and Contaminants, including Arsenic. Lyon, International Agency for Research on Cancer 2002, (IARC *Monographs on the Evaluation of Carcinogenic Risks to Humans*, Volume 84).

James MO, Yan Z, Cornett R, Jayanti VM, Henderson GN, Davydova N, Katovich MJ, Pollock B, Stacpoole PW. Pharmacokinetics and metabolism of [<sup>14</sup>C]dichloroacetate in male Sprague-Dawley rats. Identification of glycine conjugates, including hippurate, as urinary metabolites of dichloroacetate. *Drug metabolism and disposition: The biological fate of chemicals*, 1998, 26(11):1134-43.

James, M.O., R. Cornett, Z. Yan, G.N. Henderson and P.W. Stacpoole. 1997. Glutathione-dependent conversion to glyoxylate, a major pathway of DCA biotransformation in hepatic cytosol from humans and rats, is reduced in DCA-treated rats. *Drug metabolism and disposition* 25(11):1223-1227.

Kato-Weinstein J, Lingohr MK, Orner GA, Thrall BD, Bull RJ. Effects of dichloroacetate on glycogen metabolism in B6C3F1 mice. *Toxicology*, 1998, 130:141-154.

Katz R, Tai CN, Diener RM, McConnell RF, Semonick DE. Dichloroacetate, sodium: 3-Month oral toxicity studies in rats and dogs. *Toxicology and applied pharmacology*, 1981, 57: 273-287.

Katz R, et al. Dichloroacetate: 90 day oral administration in rats. 1978, Summit, NJ. Ciba-Geigy.

Kim H & Weisel CP. Dermal absorption of dichloro- and trichloroacetic acids from chlorinated water. *Journal of exposure analysis and environmental epidemiology*, 1998, 8(4):555-575.

Kim, H; Haltmeier, P; Klotz, JB; et al. Evaluation of biomarkers of environmental exposures: Urinary haloacids associated with ingestion of chlorinated drinking water. *Environ Res*, 1999, 80:187-195.

Lantum, HBM; Board, PG; Anders, MW. Kinetics of the biotransformation of maleylacetone and chlorofluoroacetate by polymorphic variants of human glutathione transferase zeta (hgstZ1-1). *Chem Res Toxicol*, 2002, 15:957-963.

- 
- Latendresse JR & Pereira MA. Dissimilar characteristics of N-methyl-N-nitrosourea-initiated foci and tumors promoted by dichloroacetic acid or trichloroacetic acid in the liver of female B6C3F1 mice. *Toxicologic pathology*, 1997, 25(5): 433-440.
- Leavitt SA, DeAngelo AB, George MH, Ross JA. Assessment of the mutagenicity of dichloroacetic acid in lacI transgenic B6C3F1 mouse liver. *Carcinogenesis*, 1997, 18(11): 2101-2106.
- Linder RE, Klinefelter GR, Strader LF, Suarez JD, Roberts NL. Spermatotoxicity of dichloroacetic acid. *Reproductive toxicology*, 1997, 11(5): 681-688.
- Lukas G, Vyas KH, Brindle SD, LeSher AR, Wagner WE, Jr. Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration. *Journal of pharmacology science*, 1980, 69(4): 419-421.
- Lykins, B.W., Goodrich, J.A., Koffskey, W.E. and Griese, M.H. (1991) Controlling disinfection by-products with alternative disinfectants. Proceedings of the 1991 Annual Conference of the American Water Works Association, Water Quality for the New Decade, 897-911.
- Moore, GW; Swift, LL; Rabinowitz, D; et al. (1979) Reduction of serum cholesterol in two patients with homozygous familial hypercholesterolemia by dichloroacetate. *Atherosclerosis* 33:285-293.
- Moser VC, Phillips PM, McDaniel KL, MacPhail RC. Behavioral evaluation of the neurotoxicity produced by dichloroacetic acid in rats. *Neurotoxicology and teratology*. 1999, 21(6): 719-731.
- Nikolaou, A.D., Kostopoulou, M.N. and Lekkas, T.D. (1999) Organic by-products of drinking water chlorination. *Global Nest* 1(3), 143-155.
- Nissinen, T.K., Miettinen, I.T., Martikainen, P.J. and Vartiainen, T. (2002) Disinfection by-products in Finnish drinking waters. *Chemosphere* 48(1), 9-20.
- Parrish JM, Austin EW, Stevens DK, Kinder DH, Bull RJ. Haloacetate-induced oxidative damage to DNA in the liver of male B6C3F1 mice. *Toxicology*, 1996, 110:103-111.
- Pereira MA. Carcinogenic activity of dichloroacetic acid and trichloroacetic acid in the liver of female B6C3F1 mice. *Fundamental and applied toxicology*, 1996, 31: 192-199.
- Pereira MA & Phelps JB. Promotion by dichloroacetic acid and trichloroacetic acid of N-methyl-N-nitrosourea-initiated cancer in the liver of female B6C3F1 mice. *Cancer letters*, 1996, 102:133-141.
- Raymer J H, Pellizzari ED, Hu Y. Exposures to Water Disinfection Byproducts via Food. US Environmental Protection Agency, National Center for Environmental Research STAR Drinking Water Progress Review Meeting. February 22-23, 2001.
- Reimann S, Grob K, Frank H. Environmental chloroacetic acids in foods analyzed by GC-ECD. *Mitteilungen Aus Dem Gebiete der Lebensmitteluntersuchung und Hygiene*, 1996, 87(2): 212-222.
- Richmond RE, Carter JH, Carter HW, Daniel FB, DeAngelo AB. Immunohistochemical analysis of dichloroacetic acid (DCA)-induced hepatocarcinogenesis in male Fischer (F344) rats. *Cancer Letters*, 1995, 92: 67-76.
- Saillenfait, AM; Langonne, I; Sabate, JP. Developmental toxicity of trichloroethylene, tetrachloroethylene and four of their metabolites in rat whole embryo culture. *Arch Toxicol*, 1995, 70:71-82.
- Sanchez IM & Bull RJ. Early induction of reparative hyperplasia in B6C3F1 mice treated with dichloroacetate and trichloroacetate. *Toxicology*, 1990, 64: 33-46.

---

Schultz IR, Merdink JL, Gonzalez-Leon A, Bull JR. Comparative Toxicokinetics of Chlorinated and Brominated Haloacetates in F344 Rats. *Toxicology and applied pharmacology*, 1999, 158(2): 103-114.

Schultz, IR; Merdink, JL; Gonzalez-Leon, A; et al. Dichloroacetate toxicokinetics and disruption of tyrosine catabolism in B6C3F1 mice: dose-response relationships and age as a modifying factor. *Toxicology*, 2002,173:229-247.

Singer, P.C., Obolensky, A. and Greiner, A. (1995) DBPs in chlorinated North Carolina drinking waters. *Journal American Water Works Association* 87(10), 83-92.

Smith MK, Weller E, Chinchilli V, Read EJ, Christ SA, Randall JL, Kavlock RJ. Statistical analysis of a developmental toxicity interaction study. *Teratology*, 1992, 118: 488-489.

Smyth HF, Carpenter CP, Weil CS. Range-finding toxicity data: List IV. American Medical Association Archives, *Industrial hygiene and occupational medicine*, 1951. 4:119-122.

Sprijjt, L; Naviaux, RK; McGowan, KA; et al. Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate. *Muscle Nerve*, 2001, 24:916-924.

Stacpoole PW, Henderson GN, Yan Z, James MO. Clinical pharmacology and toxicology of dichloroacetate. *Environmental health perspectives*, 1998a. 106(Suppl. 4): 989-994.

Stacpoole, PW; Barnes, CL; Hurbanis, MD; et al. Treatment of congenital lactic acidosis with dichloroacetate. *Arch Disease Childhood*, 1998b, 77:535-541.

Stacpoole PW. The pharmacology of dichloroacetate. *Metabolism*, 1989. 38(11):1124-1144.

Stacpoole PW. Dichloroacetate derivatives. Metabolic effects and pharmacodynamics in normal rats. *Life Sciences*, 1987. 41:2167-2176.

Stacpoole PW, Moore GW, Kornaus D. Toxicity of chronic dichloroacetate. *New England journal of medicine*, 1979. 300:72 (letter).

Stacpoole PW, Moore GW, Kronauser DM. Metabolic effects of dichloroacetate in patients with diabetes mellitus and hyperlipoproteinemia. *New England journal of medicine*, 1978. 298:526-530.

Stauber, AJ, Bull RJ. Differences in phenotype and cell replicative behavior of hepatic tumors induced by dichloroacetate (DCA) and trichloroacetate (TCA). *Toxicology and applied pharmacology*, 1997. 144(2): 235-46.

Tao L, Li K, Kramer PM, Pereira MA. Loss of heterozygosity on chromosome 6 in dichloroacetic acid and trichloroacetic acid-induced liver tumors in female B6C3F<sub>1</sub> mice. *Cancer letters*, 1996, 108: 257-261.

Thai, SF; Allen, JW; DeAngelo, AB; et al. Altered gene expression in mouse livers after dichloroacetic acid exposure. *Mutat Res*, 2003, 543(2):167-180.

Thai, SF; Allen, JW; DeAngelo, AB; et al. Detection of early gene expression changes by differential display in the livers of mice exposed to dichloroacetic acid. *Carcinogenesis*, 2001, 22:1317-1322.

Tong Z, Board PG, Anders MW. Glutathione transferase Zeta catalyzes the oxygenation of the carcinogen DCA to glyoxylic acid. *Biochemistry journal*, 1998a, 331(2):371-374.

---

Tong Z, Board PG, Anders MW. Glutathione transferase zeta-catalyzed biotransformation of dichloroacetic acid and other alpha-haloacids. *Chemical research in toxicology*, 1998b, 11: 1332-1338.

Tzeng, H-F, Blackburn, AC; Board, PG; et al. (2000) Polymorphism- and species-dependent inactivation of glutathione transferase zeta by dichloroacetate. *Chem Res Toxicol* 13: 231-236.

US EPA. Environmental Protection Agency. Toxicological review of dichloroacetic acid. In support of summary information on Integrated Risk Information System (IRIS). National Center for Environmental Assessment, Washington, DC. 2003.

USEPA. Environmental Protection Agency. Stage 2 Occurrence Assessment for Disinfectants and Disinfection ByProducts (D/DBPs), 2001b.

US EPA. Environmental Protection Agency. Guidelines for carcinogen risk assessment. (SAB Review Draft). Risk Assessment Forum, Washington, DC, 1999. NCEA-F-0644.

US EPA. Environmental Protection Agency. 40CFR Parts 9, 141, and 142. National Primary Drinking Water Regulations: Disinfectants and Disinfection Byproducts; Final Rule, 1998a, *Federal Register* 63: 69390-69476.

US EPA. Environmental Protection Agency. Method 552.2. Determination of haloacetic acids and dalapon in drinking water by liquid-liquid extraction, derivatization and gas chromatography with electron capture detection. Revision 1.0. National Exposure Research Laboratory Office of Research and Development. US Environmental Protection Agency, Cincinnati, Ohio 45268, 1995.

US EPA. Environmental Protection Agency. Final draft for the drinking water criteria document on chlorinated acids/aldehydes/ketones/alcohols. Prepared for Health and Ecological Criteria Division, Office of Science and Technology, Office of Water, US Environmental Protection Agency, Washington, DC 20460. EPA 68-C2-0139, 1994.

US EPA. Environmental Protection Agency. Toxicology of the chloroacetic acids, by-products of the drinking water disinfection process. II. The comparative carcinogenicity of dichloroacetic and trichloroacetic acid: Implication for risk assessment. Document No. HERL-0820. Research Triangle Park, NC: Health Effects Research Laboratory, U.S. EPA, 1991.

US EPA. Environmental Protection Agency. Guidelines for carcinogen risk assessment, 1986, *Federal Register* 51(185): 33992-34003.

Vershueren K. Handbook of environmental data on organic chemicals. 1977. New York, NY, Van Nostrand Reinhold.

Weast, RC ed. Handbook of chemistry and physics. Cleveland, OH, *CRC Press*.1988.

WHO. World Health Organization. Guidelines for drinking-water quality. Volume 2, health criteria and other supporting information. Second ed, 1996. *World Health Organization*, Geneva.

WHO. World Health Organization. Environmental health criteria 216. disinfectants and disinfectant by-products. World Health Organization, Geneva, 2000. Available at: <http://www.inchem.org/>

Woodard G, et al. The acute oral toxicity of acetic, chloroacetic, dichloroacetic and trichloroacetic acids. *Journal of industrial hygiene and toxicology*, 1941, 23:78-82.